Профилактика спида и вирусного гепатита при переливании компонентов крови

Профилактика спида и вирусного гепатита при переливании компонентов крови

1. Pimenov N.N. Jepidemiologija i infekcionnye bolezni. 2012;3:4-10 (in Russian).

2. Trifonova G.F. Infekcija i immunitet. 2014;4(3): 267-74 (in Russian).

3. Sinajskaja E.V. Jepidemiologija i infekcionnye bolezni. 2012;6: 21-5 (in Russian).

4. Suhoruk A.A. Zhurnal infektologii. 2014;.6(1): 67-71 (in Russian).

5. Jushhuk N.D. Ter. arhiv. 2014;86(10): 77-81 (in Russian).

6. Tarasenko O.A. Vestnik Rossijskogo gosudarstvennogo medicinskogo universiteta. 2010; 2:51-3 (in Russian).

7. Nikolaeva LI, Archakov AI, Blokhina NP, et al. Virusspecific antibody titres in different phases of hepatitis С virus infection. Viral Hepatitis. 2002. Vol.9(6):429-7.

8. Beljakova V.V. Gematologija i transfuziologija. 2014:59(1):15-18 (in Russian).

9. Chechetkin A.V. Transfuziologija. 2014:15(3):4-13 (in Russian).

10. van Hoeven LR, Janssen MP, Rautmann G. The collection, testing and use of blood and blood components in Europe. 2011 report // Directorate for the quality of medicines and healthcare of the Council of Europe (EDQM);2014.64 р.

11. Roth WK. Quarantine Plasma: Quo vadis? Transfusion Medicine & Hemotherapy. 2010 June;37(3):118-2.

12. Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood. 1999 Aug 15;94(4):1183-91.

13. Maple PA, McKee Т, Desselberger U., Wreghitt T.G. Hepatitis С virus infections in transplantant patients: serological and virological investigations. J Med Virol. 1994 Sep;44(1):43-8.

14. AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med. 1997 Nov 15;127(10):904-9.

15. Lefrèe JJ, Guiramand S, Lefrere F, et al. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis. 1997 Feb;175(2):316-22.

16. Humpe A, Legler TJ, Nübling CM, et al. Hepatitis C virus transmission through quarantine fresh-frozen plasma. Thromb Haemost. 2000 Nov;84(5):784-8.

17. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010 Jul;50(7):1495-504.

18. Mller-Breitkreutz K, Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J Med Virol. 1998 Nov;56(3):239-45.

19. Keil SD, Bengrine A, Bowen R, et al. Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion. 2015 Mar . doi: 10.1111/trf.13030.

20. Salado W., Sumian C., Dehaut F. et al. In-vitro evaluation of platelet concentrates pathogen reduced with Theraflex uv-platelets procedure. In: Abstracts of the 33rd International Congress of the International Society of Blood Transfusion, in conjunction with the 33rd Congress of the KSBT and the 2014 Congress of the Korean Hematology Societies, Seoul, Korea, May 31-June 5, 2014. Vox Sang. 2014 Jun;107 Suppl 1:129.

21. V. Brixner, J. Leibacher, K. Janetzko et al. Validation of the S-303 pathogen inactivation system for RBC components. In: Abstracts of the 23rd Regional Congress of the International Society of Blood Transfusion. Amsterdam, Netherlands. June 2-5, 2013. Vox Sang. 2013 Jun;105 Suppl 1:145.

22. Reddy H.L., Doane S.K., Keil S.D. et al. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion. 2013 Jan;53 Suppl 1:131S-136S.



Источник: journal.niidi.ru

Читайте также
Вид:

Добавить комментарий